Literature DB >> 20561904

Trigeminal antihyperalgesic effect of intranasal carbon dioxide.

Alexander Z Tzabazis1, Sharon H Niv, Neil A Manering, Mikhail Klyukinov, Jason M Cuellar, Anish Bhatnagar, David C Yeomans.   

Abstract

AIMS: Clinical studies demonstrate attenuation of trigeminal-related pain states such as migraine by intranasal CO(2) application. This study investigated the underlying mechanisms of this observation and its potential use to reverse trigeminal pain and hypersensitivity. MAIN
METHODS: We used a behavioral rat model of capsaicin-induced trigeminal thermal hyperalgesia, intranasal CO2 application and several pharmacologic agents such as carbonic anhydrase, acid-sensing ion channels (ASICs), and TRPV1 blocker as well as acidic buffer solutions to investigate and mimic the underlying mechanism. KEY
FINDINGS: Intranasal CO(2) application produced a robust dose-dependent antihyperalgesic effect in rats that lasted at least one hour. Blockade of nasal carbonic anhydrase with a dorzolamide solution (Trusopt ophthalmic solution) showed only a non-significant decrease of the antihyperalgesic effect of intranasal CO(2) application. Pharmacologic blockade of ASICs or TRPV(1) receptor significantly attenuated the antihyperalgesic effect of CO(2) application. The effect of intranasal CO(2) application could be mimicked by application of pH 4, but not pH 5, buffer solution to the nasal mucosa. As with CO(2) application, the antihyperalgesic effect of intranasal pH 4 buffer was blocked by nasal application of antagonists to ASICs and TRPV(1) receptors. SIGNIFICANCE: Our results indicate that intranasal CO(2) application results in a subsequent attenuation of trigeminal nociception, mediated by protonic activation of TRPV(1) and ASIC channels. A potential central mechanism for this attenuation is discussed. The antihyperalgesic effects of intranasal CO(2) application might be useful for the treatment of trigeminal pain states. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20561904      PMCID: PMC2900516          DOI: 10.1016/j.lfs.2010.05.013

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  25 in total

1.  Peripheral and central nervous changes in patients with rheumatoid arthritis in response to repetitive painful stimulation.

Authors:  T Hummel; C Schiessl; J Wendler; G Kobal
Journal:  Int J Psychophysiol       Date:  2000-08       Impact factor: 2.997

2.  Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: electrophysiological evidence.

Authors:  David C Yeomans; Herbert K Proudfit
Journal:  Pain       Date:  1996-11       Impact factor: 6.961

3.  The mucosal potential elicited by noxious chemical stimuli with CO2 in rats: is it a peripheral nociceptive event?

Authors:  N Thürauf; I Friedel; C Hummel; G Kobal
Journal:  Neurosci Lett       Date:  1991-07-22       Impact factor: 3.046

4.  Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: behavioral evidence.

Authors:  David C Yeomans; Vesna Pirec; Herbert K Proudfit
Journal:  Pain       Date:  1996-11       Impact factor: 6.961

5.  Low but not high rate noxious radiant skin heating evokes a capsaicin-sensitive increase in spinal cord dorsal horn release of substance P.

Authors:  V Zachariou; B D Goldstein; D C Yeomans
Journal:  Brain Res       Date:  1997-03-28       Impact factor: 3.252

6.  The spinal transmission of nociceptive information: modulation by the caudal medulla.

Authors:  D Bouhassira; D Chitour; L Villaneuva; D Le Bars
Journal:  Neuroscience       Date:  1995-12       Impact factor: 3.590

7.  Functional properties of the high-affinity TRPV1 (VR1) vanilloid receptor antagonist (4-hydroxy-5-iodo-3-methoxyphenylacetate ester) iodo-resiniferatoxin.

Authors:  Guy R Seabrook; Kathy G Sutton; Wolfgang Jarolimek; Gregory J Hollingworth; Simon Teague; Janine Webb; Natalie Clark; Susan Boyce; Julie Kerby; Zahid Ali; Margaret Chou; Richard Middleton; Gregory Kaczorowski; A Brian Jones
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

8.  Ocular hypotensive effects of anti-glaucoma agents in mice.

Authors:  Takahiro Akaishi; Noriko Odani-Kawabata; Naruhiro Ishida; Masatsugu Nakamura
Journal:  J Ocul Pharmacol Ther       Date:  2009-10       Impact factor: 2.671

9.  Controlled noxious chemical stimulation: responses of rat trigeminal brainstem neurones to CO2 pulses applied to the nasal mucosa.

Authors:  F Anton; P Peppel; I Euchner; H O Handwerker
Journal:  Neurosci Lett       Date:  1991-02-25       Impact factor: 3.046

Review 10.  Pain in the trigeminal system: irritation of the nasal mucosa using short- and long-lasting stimuli.

Authors:  Thomas Hummel; Parvaneh Mohammadian; Robert Marchl; Gerd Kobal; Jörn Lötsch
Journal:  Int J Psychophysiol       Date:  2003-02       Impact factor: 2.997

View more
  7 in total

1.  Channels: A TR(i)P in the air.

Authors:  Peter M Zygmunt
Journal:  Nat Chem Biol       Date:  2011-09-19       Impact factor: 15.040

2.  Effect of Isoflurane Anesthesia on Circadian Metabolism and Physiology in Rats.

Authors:  Melissa A Wren-Dail; Robert T Dauchy; David E Blask; Steven M Hill; Tara G Ooms; Lynell M Dupepe; Rudolf P Bohm
Journal:  Comp Med       Date:  2017-03-01       Impact factor: 0.982

3.  Dissecting the role of TRPV1 in detecting multiple trigeminal irritants in three behavioral assays for sensory irritation.

Authors:  C J Saunders; Winston Y Li; Tulsi D Patel; Jeffrey A Muday; Wayne L Silver
Journal:  F1000Res       Date:  2013-03-05

4.  Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder.

Authors:  Mohammad Obaidi; Elliot Offman; John Messina; Jennifer Carothers; Per G Djupesland; Ramy A Mahmoud
Journal:  Headache       Date:  2013-08-28       Impact factor: 5.887

Review 5.  Current and Innovative Pharmacological Options to Treat Typical and Atypical Trigeminal Neuralgia.

Authors:  G Di Stefano; A Truini; G Cruccu
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

6.  No relevant modulation of TRPV1-mediated trigeminal pain by intranasal carbon dioxide in healthy humans.

Authors:  Tim P Jürgens; Romy Reetz; Arne May
Journal:  J Headache Pain       Date:  2013-04-10       Impact factor: 7.277

7.  Gene therapy for trigeminal pain in mice.

Authors:  A Z Tzabazis; M Klukinov; D P Feliciano; S P Wilson; D C Yeomans
Journal:  Gene Ther       Date:  2014-02-27       Impact factor: 5.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.